Several Indian companies, including Larsen & Toubro, Godrej Consumer Products, and Dr Reddys Laboratories, are expected to record double-digit growth in their topline and bottomline figures for the March quarter due to healthy execution and strong order books. L&Ts core engineering business is expected to drive the topline with a healthy opening order book. Meanwhile, Revlimid, the cancer drug, is expected to have contributed significantly to growth in Dr Reddys US sales. Godrej Consumer Products is expected to perform well due to an anticipated rebound in Indonesia.